Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Chondroitin wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Probably helps
8 of 13 studies with measurable effects showed benefit.
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
800-1200mg
With meals, Once daily or split into 2-3 doses
Chondroitin sulfate from bovine or marine sources
Prescription-only, clinician-titrated. Subcutaneous (Wegovy weight management: escalate to 2.4 mg once weekly; Ozempic diabetes: 0.5-2.0 mg once weekly). Oral (Rybelsus diabetes: 3-14 mg once daily). DO NOT self-dose.
any
Subcutaneous once-weekly injection (Ozempic / Wegovy)
8-12 weeks
12+ weeks
6-24 months
Weeks to months
Months (titrated over 16-20 weeks)
Months to years
Especially during dose escalation
Meta-analysis: chondroitin for osteoarthritis of the knee or hip
Annals of internal medicine (2007) · Meta analysis · n=3846
Large-scale, methodologically sound trials indicate that the symptomatic benefit of chondroitin is minimal or nonexistent.
The Safety and Efficacy of Glucosamine and/or Chondroitin in Humans: A Systematic Review
Nutrients (2025) · Systematic review · n=146
Of the 2013 articles screened, 146 studies were included in our review, with nearly 60% being randomized controlled trials and most conducted in Europe, Asia, or the U.S.
Systematic review and network meta-analysis on the efficacy and safety of parmacotherapy for hand osteoarthritis
PloS one (2024) · Meta analysis · n=3965
GCSB-5, a specific herbal complex that mainly regulate pain in hand osteoarthritis, showed the greatest reduction in pain [WMD = -13.00, 95% CI (-26.69, 0.69)].
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1).
N Engl J Med (2021) · Rct · n=1961
Double-blind RCT in 1,961 adults with obesity/overweight WITHOUT diabetes, randomized 2:1 to subcutaneous semaglutide 2.4 mg/week or placebo plus lifestyle for 68 weeks
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT).
N Engl J Med (2023) · Rct · n=17604
Large cardiovascular-outcomes RCT: 17,604 patients with preexisting cardiovascular disease and overweight/obesity but WITHOUT diabetes
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6).
N Engl J Med (2016) · Rct · n=3297
Pre-approval cardiovascular-safety RCT in 3,297 patients with type 2 diabetes at high cardiovascular risk, semaglutide (0.5/1.0 mg/week) vs placebo for 104 weeks
Large meta-analyses show minimal to nonexistent benefits. Effects appear modest at best, with significant study heterogeneity. Combination with glucosamine may be more effective than chondroitin alone.
AI-estimated from published studies. Interpret as directional guidance.
Chondroitin has a higher evidence score (5.5/10 vs 8.5/10) and wins in 2 of 3 categories.
No known interactions between Chondroitin and Semaglutide have been documented in our database. However, always consult a healthcare provider before combining supplements.